Follow us on Twitter
twitter icon@FreshPatents


Platelet patents

      

This page is updated frequently with new Platelet-related patent applications.




 Insulating tape, use thereof as electrical insulation for electrical machines, electrical insulation, and  producing the insulating tape patent thumbnailInsulating tape, use thereof as electrical insulation for electrical machines, electrical insulation, and producing the insulating tape
An insulating tape in the form of a particle composite for an electrical insulating tape, use of such insulating tape as insulation, and the production of the insulating tape are disclosed. To produce the insulating tape, electrically insulating, platelet-shaped particles are connected by an electrically insulating binder to an electrical insulating material in the form of an at least partially porous insulating tape.
Siemens Aktiengesellschaft


 Blood analyzer, blood analyzing method, and non-transitory computer-readable storage medium patent thumbnailBlood analyzer, blood analyzing method, and non-transitory computer-readable storage medium
Disclosed is a blood analyzer including a specimen preparation unit that prepares a measurement specimen by mixing a hemolytic agent that hemolyzes red blood cells, a staining dye that dyes nucleic acids, and a blood specimen; a detector that detects intensity of side scattered light and intensity of fluorescence generated with application of light from the measurement specimen prepared by the specimen preparation unit; and an analysis unit that discriminates white blood cells from giant platelets based on the intensity of side scattered light and the intensity of fluorescence detected by the detector, and counts the white blood cells.. .
Sysmex Corporation


 Process for unitary graphene layer or graphene single crystal patent thumbnailProcess for unitary graphene layer or graphene single crystal
A unitary graphene layer or graphene single crystal containing closely packed and chemically bonded parallel graphene planes having an inter-graphene plane spacing of 0.335 to 0.40 nm and an oxygen content of 0.01% to 10% by weight, which unitary graphene layer or graphene single crystal is obtained from heat-treating a graphene oxide gel at a temperature higher than 100° c., wherein the average mis-orientation angle between two graphene planes is less than 10 degrees, more typically less than 5 degrees. The molecules in the graphene oxide gel, upon drying and heat-treating, are chemically interconnected and integrated into a unitary graphene entity containing no discrete graphite flake or graphene platelet.
Nanotek Instruments, Inc.


 Compositions and methods for anti-lyst immunomodulation patent thumbnailCompositions and methods for anti-lyst immunomodulation
Excessive or repeated activation of inflammatory and pro-coagulant mechanisms at the site of tissue injury contributes to the development scar tissue that can lead to intimal hyperplasia and fibrotic disease. It has been established that inhibition of the lyst protein is associated with reduced inflammatory responses and reduced platelet activation at the site of tissue damage.
Research Institute At Nationwide Children's Hospital


 Platelet-derived growth factor compositions and methods of use thereof patent thumbnailPlatelet-derived growth factor compositions and methods of use thereof
A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/ml to about 1.0 mg/ml in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.. .
Biomimetic Therapeutics, Llc


 Platelet-derived growth factor compositions and methods of use thereof patent thumbnailPlatelet-derived growth factor compositions and methods of use thereof
A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/ml to about 1.0 mg/ml in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.. .
Biomimetic Therapeutics, Llc


 Extracellular matrix grafts loaded with exogenous factors patent thumbnailExtracellular matrix grafts loaded with exogenous factors
The present disclosure provides bioactive compositions, methods of making bioactive compositions, and methods of treating a patient using such bioactive compositions. In some forms the bioactive composition of the present disclosure comprises a collagenous biomaterial and a bioactive fraction of mammalian platelets applied to the collagenous biomaterial..
Cook Biotech Incorporated


 Detection of platelet-derived shed cd31 patent thumbnailDetection of platelet-derived shed cd31
The present invention relates to various soluble forms of cd31, including a novel form which is shed by activated platelets and released into the circulation. Methods for detecting said soluble forms of cd31 are disclosed, as are methods of specifically 1 detecting said platelet-derived shed cd31 and the use of such methods as a diagnostic tool..
Assistance Publique - Hopitaux De Paris


 Par-1 activation by metalloproteinase-1 (mmp-1) patent thumbnailPar-1 activation by metalloproteinase-1 (mmp-1)
Matrix metalloproteases (mmps) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (par-1) by endogenous platelet mmp-1 collagenase on the surface of platelets.
Tufts Medical Center, Inc.


 Lipoprotein nanoplatelets:  fluorescent, zwitterionic probes for molecular and cellular imaging patent thumbnailLipoprotein nanoplatelets: fluorescent, zwitterionic probes for molecular and cellular imaging
Compositions are provided comprising water-stable semi-conductor nanoplatelets encapsulated in a hydrophilic coating further comprising lipids and lipoproteins. Uses include biomolecular imaging and sensing, and methods of making comprise: colloidal synthesis of cdse core npls; layer-by-layer growth of a cds shell; and encapsulation of cdse/cdscore/shell npls in lipid and lipoprotein components through an evaporation-encapsulation using zwitterionic phospholipids, detergents, and amphipathic membrane scaffold proteins..
The Board Of Trustees Of The University Of Illinois


Megakaryocytic particles and microparticles for cell therapy & fate modification of stem and progenitor cells

Applications in transfusion medicine requiring platelets, and hematopoietic stem-cell transplantations require either platelets or enhancement of in vivo platelet biogenesis. Gene therapy applications of hematopoietic stem and progenitor cells (hspcs) require effective and specific modification of hspcs by dna, rna or other biological molecules.

Graphene sheet combining graphite flake structure and its manufacturing method, and slurry for manufacturing the same

A graphene sheet combining graphite flake structure includes a graphite nanoplatelet material and a graphene material. The graphene material is mixed in the graphite nanoplatelet material, and the content of the graphene material is between 1% and 80% of the graphite nanoplatelet material.
Nitronix Nanotechnology Corporation

Substituted pyridazines as prostacyclin receptor modulators

Cyclohexane derivatives of formula ia and pharmaceutical compositions thereof that modulate the activity of the pgi2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (pah) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (sle); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (copd)..
Arena Pharmaceuticals, Inc.

Combined autologous biologic and cold therapy treatment of skin injuries

This disclosure describes a combined autologous biologic and cold therapy treatment for treating various skin injuries. The treatment may include applying autologous blood components, including but not limited to platelet rich plasma, to a skin injury in a manner that influences the healing process.
Arthrex, Inc.

Pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma and method using the same

Provided are a pharmaceutical composition for preventing or treating sensorineural hearing loss or tinnitus including platelet-rich plasma, and a method of preventing or treating sensorineural hearing loss or tinnitus using the same.. .

Combined autologous biologic and cold therapy treatment of skin injuries

This disclosure describes a combined autologous biologic and cold therapy treatment for treating various skin injuries. The treatment may include applying autologous blood components, including but not limited to platelet rich plasma, to a skin injury in a manner that influences the healing process.
Arthrex, Inc.

Superabsorbent polymers and sunscreen actives for use in skin care compositions

A skin care composition having from about 0.01% to about 5%, by weight, of an superabsorbent polymer which is a sodium polyacrylate, sodium polacrylate starch, sodium acrylates crosspolymer-2 or mixtures of these and a portion of the polymer comprises a grafted starch material. The superabsorbent polymer is particulate where the particles have an average particle size in the range of from about 5μ-30μ, and the individual particles in their dry or un-swollen condition are substantially non-spherical, flat, platelet, or elongated in shape.
The Procter & Gamble Company

Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Provided herein are methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated in individuals diagnosed with or thought to have essential thrombocythemia (et). Also provided herein are methods for using telomerase inhibitors for maintaining blood platelet counts at relatively normal ranges in the blood of individuals diagnosed with or suspected of having et..
Geron Corporation

Methods of treating transplant rejection using a domain antibody directed against cd40

Methods of treating renal transplant rejection using anti-cd40l domain antibodies are provided. The anti-cd40l dabs are less likely to cause platelet aggregation and thus cause thromboembolism.
Bristol-myers Squibb Company

Acoustic blood separation processes and devices

Acoustophoretic devices are disclosed. The devices include a flow chamber, an ultrasonic transducer, a reflector, an inlet, a filtrate outlet, a concentrate outlet, and optionally a lipid collection trap.
Flodesign Sonics, Inc.

Maintenance of platelet inhibition during antiplatelet therapy

A method for reducing or maintaining platelet inhibition in a patient by administering cangrelor prior to an invasive procedure is described. The method of this invention can be used for patients in need of antiplatelet therapy or at risk of thrombosis.
The Medicines Company

Freeze-dried polymer compositions for mixing with platelet rich plasma to form implants for tissue repair and/or compositions for therapeutic intra-articular injections

The present application relates to a freeze-dried polymer composition containing chitosan and at least one lyoprotectant, a process for preparing a freeze-dried composition containing chitosan and at least one lyoprotectant and the use of a reconstituted freeze-dried chitosan composition to prepare implants for tissue repair.. .
Ortho Regenerative Technologies Inc.

Chimeric clotting factors

Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.. .
Biogen Hemophilia Inc.

Filler pigments

Filler pigments based on platelet-shaped substrates, which are coated with barium sulfate and at least two metal oxides and/or metal hydroxides are highly suitable as filler pigments especially for cosmetic formulations.. .
Merck Patent Gmbh

Treatment of thrombocytopenia using orally administered interferon

An interferon composition is provided for enhancing the platelet count, reducing the recurrence rate of hepatitis, and/or improving the social function of hepatitis patients. The method comprises administering a low dose of ifn (about 5 iu to about 2500 iu of ifn-alpha) to a patient in need thereof.
Amarillo Biosciences, Inc.

Treatment of tumors expressing mutant p53

Pdgfrb inhibitors and the use of such inhibitors to treat mutant p53-expressing tumors are described. The present disclosure encompasses the discovery that mutant p53-induced upregulation of the platelet-derived growth factor receptor b (pdgfrb) contributes to invasion and/or metastasis of tumors expressing mutant p53.
Sloan-kettering Institute For Cancer Research

Graphene-augmented composite materials

Composite materials are augmented with functionalized graphene having added amine groups, benzoxazine groups, imide groups, or a combination of amine groups and imide groups on a surface of the graphene, epoxide groups formed on at least one edge of the graphene and/or holes formed through the graphene. The functionalized graphene is integrated into a composite material as a supplement to or as a replacement for either the carbon reinforcement material or the resin matrix material to increase strength of the composite materials, and may be in the form of a functionalized graphene nanoplatelet, a flat graphene sheet or film, or a rolled or twisted graphene sheet or film..
The Boeing Company

Targeted therapy to restore radioactive iodine transport in thyroid cancer

The invention includes method, pharmaceutical compositions and uses thereof for treating patients with papillary thyroid carcinoma (ptc) using a platelet derived growth factor receptor alpha (pdgfra) inhibitor. The pdgfra inhibitor is preferably an antibody specific to pdgfra and causes an increase in the sensitivity level of ptc cells to radioiodine treatment.
The Governors Of The University Of Alberta

Implantable device for automatic delivery of medication for allergic reactions

Apparatus, implanted subcutaneously or in muscle, fat, joint spaces, or body cavities of any type, detects and responds to an allergic and/or anaphylactic reaction. Detection is carried out by monitoring the levels of biomarker molecules that indicate the occurrence of an allergic and/or anaphylactic reaction, such as: histamine, leukotrienes, prostaglandins, cytokines, tryptase, fc-ε-ri complexes, anaphylatoxin c3a, chymase, carboxypeptidase a, platelet-activating factor8, other mast cell degranulation byproducts, or other basophil activation compounds.

Serum fraction of platelet-rich fibrin

And further provides for the isolated serum fraction obtained by such method, and its medical use.. .

Catalyst layer

A catalyst layer including: (i) a platinum-containing electrocatalyst; (ii) an oxygen evolution reaction electrocatalyst; (iii) one or more carbonaceous materials selected from the group consisting of graphite, nanofibres, nanotubes, nanographene platelets and low surface area, heat-treated carbon blacks wherein the one or more carbonaceous materials do not support the platinum-containing electrocatalyst; and (iv) a proton-conducting polymer and its use in an electrochemical device are disclosed.. .
Johnson Matthey Fuel Cells Limited

Blood state analysis device, blood state analysis system, blood state analysis method, and storage device

A blood state analysis device (1) that analyzes a state of a blood sample, as used for clotting time testing, said blood sample comprising a plasma and at least one reagent, including a correction unit (11) configured to correct a measured blood coagulation evaluation result of the blood sample based on a relation between reference concentrations of the at least one reagent in plasma and reference blood coagulation evaluation results, the at least one reagent is an anticoagulation treatment releasing agent, a coagulation activator, an anticoagulant, a platelet activator, an antiplatelet drug, or a combination thereof and is present in the blood sample. For instance, such device (1) allows to correct blood clotting time results with respect to concentrations of an anti-coagulant drug present in the blood sample..
Sony Corporation

Five-port blood separation chamber and methods of using the same

Systems and methods are provided for separating blood into two or more separated blood components. The system includes a blood separation chamber with a single stage having five ports connected thereto.
Fenwal, Inc.

Blood condition analysis device, blood condition analysis system, blood condition analysis method, and blood condition analysis program for causing computer to implement the method

Provided is a blood condition analysis device, for analyzing the condition of a blood sample having added thereto at least one kind of drug selected from the group consisting of anticoagulation treatment canceling agents, coagulation activators, anticoagulants, platelet activators, and antiplatelet agents, the device including a drug dosage control unit for controlling the dosage of the drug to be added to the blood sample on the basis of the hematocrit and/or hemoglobin content of the blood sample.. .

Gas barrier fabric

A gas barrier fabric is disclosed. The barrier fabric includes a fabric substrate.
Goodrich Corporation

Low frequency ultrasonic vibration assisted bleeding-less surgical tool

The present invention is a method for a bleedingless surgical tool that induces cavitation in blood vessel, tissue, and/or body fluid to facilitate platelet plug formation and induces cavitation together with a temperature rise to facilitate fibrin formation, inducing and enhancing blood clotting such that bleeding does not occur while cutting is in progress. The present invention is further a bleedingless surgical tool comprising a cutting portion of the surgical tool and an ultrasonic vibration generating portion forming by an ultrasonic alternating power source and an ultrasonic vibration transducer, which during cutting of live tissues and blood vessels induces cavitation in the blood vessel, tissue, and/or body fluid to facilitate platelet plug formation and induces cavitation and temperature rise to facilitate fibrin formation, inducing and enhancing blood clotting such that bleeding does not occur while the cutting is in progress..

Compositions for treating wounds

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described..

Platelet rich plasma formulations

Compositions for platelet rich plasma (prp) and neutrophil-depleted prp are provided. Methods for treating ischemia damaged tissues by delivering a prp composition, in some embodiments a neutrophil-depleted prp composition to the damaged tissue are provided.

Platelet-derived growth factor compositions and methods of use thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/ml to about 1.0 mg/ml in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.. .
Biomimetic Therapeutics, Llc

Methods for treating wounds

Novel compositions for treating wounds and promoting the healing thereof are described, including composition containing novel combinations of a carrier and recombinant platelet derived growth factor having fewer isoforms and enhanced biostability. Methods of treating wounds with novel therapeutic composition using dosing procedures leading to effective results with a minimal number of treatment applications are also described..

Platelet-derived growth factor compositions and methods of use thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/ml to about 1.0 mg/ml in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.. .
Biomimetic Therapeutics, Llc

Platelet-derived growth factor compositions and methods of use thereof

A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived growth factor at a concentration in the range of about 0.1 mg/ml to about 1.0 mg/ml in a pharmaceutically acceptable liquid carrier and a pharmaceutically-acceptable solid carrier.. .
Biomimetic Therapeutics, Llc

Method and automated platelet identification within a whole blood sample from microscopy images

A method and apparatus for identifying platelets within a whole blood sample. The method includes the steps of: a) adding at least one colorant to the whole blood sample, which colorant is operable to tag platelets; b) disposing the blood sample into a chamber defined by at least one transparent panel; c) imaging at least a portion of the sample quiescently residing within the chamber to create one or more images; and d) identifying one or more platelets within the sample using an analyzer adapted to identify the platelets based on quantitatively determinable features within the image using a analyzer, which quantitatively determinable features include intensity differences..
Abbott Point Of Care, Inc.



Platelet topics:
  • Growth Factor
  • Fibroblast
  • Nanoparticle
  • Autologous
  • Leukocytes
  • Circulation
  • Transforming Growth Factor
  • Therapeutical
  • Platelet Derived Growth Factor
  • Bone Morphogenetic Protein
  • Endothelial
  • Recombinant
  • Stem Cells
  • Respiratory System
  • Dispensing System


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.


    4.1619

    file didn't exist0

    479092 - 0 - 51